{"url_path":"/sec/espr/10-q/2026/item-3","section_key":"item-3","section_title":"Item 3 Quantitative and Qualitative Disclosures About Market Risk","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1434868/0001628280-26-032870-index.html","accession_number":"0001628280-26-032870","cik":"0001434868","ticker":"ESPR","issuer_name":"Esperion Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1434868/0001628280-26-032870-index.html","primary_entity_key":"0001434868","primary_entity_name":"Esperion Therapeutics, Inc."},"word_count":48,"has_tables":true,"body_markdown":"Item 3. Quantitative and Qualitative Disclosures About Market Risk\n\nThere have been no material changes with respect to the information appearing in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025."}